Research reporting standards for radioembolization of hepatic malignancies

Journal of Vascular and Interventional Radiology

Volumn 22, Issue 3, 2011, Pages 265-278

  Salem, Riad ^a   Lewandowski, Robert J ^a   Gates, Vanessa L ^a   Nutting, Charles W ^b   Murthy, Ravi ^c   Rose, Steven C ^d   Soulen, Michael C ^f   Geschwind, Jean Francois H ^h   Kulik, Laura ^a   Kim, Yun Hwan ^l   Spreafico, Carlo ^f,m   MacCauro, Marco ^m   Bester, Lourens ⁿ   Brown, Daniel B ^g   Ryu, Robert K W ^a   Sze, Daniel Y ^e   Rilling, William S ⁱ   Sato, Kent T ^a   Sangro, Bruno ^o   Bilbao, Jose Ignacio ^o   Jakobs, Tobias F ^q   Ezziddin, Samer ^r   Kulkarni, Suyash ^k,t   Kulkarni, Aniruddha ^t   Liu, David M ^u   Valenti, David ^v   Hilgard, Philip ^s   Antoch, Gerald ^s   Muller, Stefan P ^s   Alsuhaibani, Hamad ^w   Mulcahy, Mary F ^a   Burrel, Marta ^p   Real, Maria Isabel ^p   Spies, Stewart ^a   Esmail, Abdulredha A ^x   Raoul, Jean Luc ^y   Garin, Etienne ^y   Johnson, Mathew S ^j   Benson III, Al B ^a   Sharma, Ricky A ^z   Wasan, Harpreet ^aa   Lambert, Bieke ^ab   Memon, Khairuddin ^a   Kennedy, Andrew S ^k   Riaz, Ahsun ^a   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b Radiology Imaging Associates   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UCSD MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MEDICAL COLLEGE OF WISCONSIN   (United States)

^j INDIANA UNIVERSITY   (United States)

^k Wake Radiology Oncology   (United States)

^l Korea University College of Medicine   (South Korea)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ ST VINCENT S HOSPITAL   (Australia)

^o UNIVERSITY CLINIC OF NAVARRA   (Spain)

^p HOSPITAL CLÍNIC   (Spain)

^q UNIVERSITY OF MUNICH   (Germany)

^r UNIVERSITY OF BONN   (Germany)

^s UNIVERSITY HOSPITAL ESSEN   (Germany)

^t TATA MEMORIAL HOSPITAL   (India)

^u UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^v MCGILL UNIVERSITY   (Canada)

^w KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^x KUWAIT CANCER CONTROL CENTER   (Kuwait)

^y CENTRE EUGÈNE MARQUIS   (France)

^z UNIVERSITY OF OXFORD   (United Kingdom)

^aa IMPERIAL COLLEGE LONDON   (United Kingdom)

^ab GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; MACROSALB TC 99M; OXALIPLATIN; PANITUMUMAB; RADIOISOTOPE; TUMOR MARKER;

ABDOMINAL PAIN; ANGIOGRAPHY; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BILOMA; CANCER GROWTH; CANCER MORTALITY; CHOLECYSTITIS; COMPUTER ASSISTED TOMOGRAPHY; DEMOGRAPHY; DIGESTIVE SYSTEM ULCER; DISEASE MARKER; DOSIMETRY; HUMAN; INTRAHEPATIC BILOMA; INTRAHEPATIC CHOLANGIOCARCINOMA; LABORATORY TEST; LIVER ABSCESS; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER METASTASIS; LIVER TUMOR; LYMPHOCYTOPENIA; MEDICAL RESEARCH; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT ASSESSMENT; PATIENT MONITORING; PHYSICAL EXAMINATION; PORTAL HYPERTENSION; PRIORITY JOURNAL; RADIATION CHOLECYSTITIS; RADIATION INDUCED LIVER DISEASE; RADIATION INJURY; RADIATION PNEUMONIA; RADIOEMBOLIZATION; RADIOLOGICAL PROCEDURES; REVIEW; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STUDY DESIGN; TREATMENT INDICATION; TREATMENT RESPONSE; VASCULAR DISEASE;

EID: 79952132261     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2010.10.029     Document Type: Article

References (88)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(Suppl):S5-S16. (Pubitemid 39423365)
3. Michel J, Suc B, Montpeyroux F, et al. Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis. J Hepatol 1997; 26:1274-1280. (Pubitemid 27346640)
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699. (Pubitemid 26079803)
5. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94:572-586. (Pubitemid 44851918)
6. Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234:954-960. (Pubitemid 40250843)
7. Maddala YK, Stadheim L, Andrews JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004; 10:449-455. (Pubitemid 38380323)
8. Lencioni R, Crocetti L. Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol 2007; 10:38-46. (Pubitemid 350017806)
9. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131:461-469. (Pubitemid 44142456)
10. Carr BI. Hepatic arterial 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10(suppl):S107-S110. (Pubitemid 38240109)
11. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627-1639. (Pubitemid 44431160)
12. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009; 9:1920-1928.
13. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology Epub ahead of print Oct 30 2010.
14. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of (90)Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2007; 47:71-81.
15. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16:1641-1651. (Pubitemid 44431161)
16. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12:1711-1720. (Pubitemid 34105661)
17. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008; 247:1029-1035. (Pubitemid 351770424)
18. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31:271-279.
19. Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25:1099-1106. (Pubitemid 46596762)
20. Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74:1494-1500.
21. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009; 115:1849-1858.
22. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/ leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88:78-85. (Pubitemid 39536508)
23. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J 2010; 16:163-175.
24. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2005; 16:765-778. (Pubitemid 40847897)
25. Brown DB, Gould JE, Gervais DA, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2007; 18:1469-1478. (Pubitemid 350151879)
26. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68:13-23. (Pubitemid 46589861)
27. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655. (Pubitemid 13149996)
28. Inarrairaegui M, Martinez-Cuesta A, Rodriguez M, et al. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010; 77:1441-1448.
29. Couinaud C. Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig Surg 1999; 16:459-467. (Pubitemid 30072153)
30. Vauthey JN, Ribero D, Abdalla EK, et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 2007; 204:1016-1027. (Pubitemid 46661199)
31. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1:1-85.
32. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10(suppl):S115-S120. (Pubitemid 38240111)
33. Seo YS, Kim YJ, Um SH, et al. Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23:1267-1275.
34. Helton W, Strasberg S. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: rationale and overview of the conference. HPB (Oxford) 2003; 5:238-242. (Pubitemid 38008079)
35. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1 - technical and methodologic considerations. J Vasc Interv Radiol 2006; 17:1251-1278. (Pubitemid 44259009)
36. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3 - comprehensive literature review and future direction. J Vasc Interv Radiol 2006; 17:1571-1593. (Pubitemid 44596135)
37. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 2 - special topics. J Vasc Interv Radiol 2006; 17:1425-1439. (Pubitemid 44412994)
38. Salem R, Lewandowski RJ, Sato KT, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 2007; 10:12-29. (Pubitemid 350008084)
39. Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005; 16:911-935. (Pubitemid 40993515)
40. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30:571-592.
41. Bilbao JI, Garrastachu P, Herraiz MJ, et al. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors. Cardiovasc Intervent Radiol 2009; 33:523-531.
42. Orth RC, Wallace MJ, Kuo MD. C-arm cone-beam CT: general principles and technical considerations for use in interventional radiology. J Vasc Interv Radiol 2008; 19:814-820.
43. Wallace MJ, Murthy R, Kamat PP, et al. Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J Vasc Interv Radiol 2007; 18:1500-1507. (Pubitemid 350151867)
44. Louie JD, Kothary N, Kuo WT, et al. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol 2009; 20:606-613.
45. Rhee TK, Omary RA, Gates V, et al. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 2005; 16:1085-1091. (Pubitemid 41177121)
46. Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 2008; 31:431-438.
47. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995; 33:919-924.
48. Garin E, Rolland Y, Boucher E, et al. First experience of hepatic radio-embolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging 2009; 37:453-461.
49. American College of Radiology Guidelines and Standards Committee of the Commission on Nuclear Medicine. ACR Practice Guidelines and Technical Standards. ACR Practice Guideline for the Performance of Liver/Spleen Scintigraphy. Amended 2006 (Resolution 35). Reston, VA: American College of Radiology, 2006.
50. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-1161. (Pubitemid 27509297)
51. Kumar A, Srivastava DN, Chau TT, et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment-prospective multicenter clinical trial. Radiology 2007; 243:509-519. (Pubitemid 46649708)
52. Wong JY, Somlo G, Odom-Maryon T, et al. Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin Cancer Res 1999; 5(suppl):3224s-3231s.
53. Andreo P. Monte Carlo techniques in medical radiation physics. Phys Med Biol 1991; 36:861-920.
54. Gulec SA, Sztejnberg ML, Siegel JA, Jevremovic T, Stabin M. Hepatic structural dosimetry in (90)Y microsphere treatment: a Monte Carlo modeling approach based on lobular microanatomy. J Nucl Med 2010; 51:301-310.
55. Riaz A, Gates V, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2010 (in press).
56. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005; 25(suppl 1):S41-S55. (Pubitemid 41686061)
57. Atassi B, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 2008; 28:81-99.
58. Ibrahim SM, Nikolaidis P, Miller FH, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging. 2009; 34:566-581.
59. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49:1185-1193.
60. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009; 27:5734-5742.
61. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303:1062-1069.
62. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva: WHO, 1979.
63. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214. (Pubitemid 11167383)
64. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
65. Riaz A, Memon K, Miller FH, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic-pathologic correlation. J Hepatol Epub ahead of print Oct 23 2010.
66. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
67. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430. (Pubitemid 32844200)
68. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60.
69. Lin M, Shon IH, Wilson R, D'Amours SK, Schlaphoff G, Lin P. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET. Hepatogastroenterology 2007; 54:910-912. (Pubitemid 46903751)
70. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27:446-452.
71. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009; 20:1121-1130.
72. Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2006; 17:225-232.
73. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13:176-181. (Pubitemid 36962641)
74. Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary Sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol 2008; 19:691-697.
75. Jakobs TF, Saleem S, Atassi B, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with (90)yttrium microspheres. Dig Dis Sci 2008; 53:2556-2563.
76. Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112:1538-1546. (Pubitemid 351441166)
77. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16:1653-1659. (Pubitemid 44431162)
78. Carretero C, Munoz-Navas M, Betes M, et al. gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 2007; 102:1216-1220. (Pubitemid 46802020)
79. Murthy R, Brown DB, Salem R, et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 2007; 18:553-561. (Pubitemid 46566540)
80. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65:412-425.
81. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005; 16:937-945. (Pubitemid 40993516)
82. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29:522-529. (Pubitemid 43822993)
83. Stangl DK. Bridging the gap between statistical analysis and decision making in public health research. Stat Med 2005; 24:503-511. (Pubitemid 40253602)
84. Rothmann M, Li N, Chen G, Chi GY, Temple R, Tsou HH. Design and analysis of non-inferiority mortality trials in oncology. Stat Med 2003; 22:239-264. (Pubitemid 36163584)
85. Omary RA, Bettmann MA, Cardella JF, et al. Quality improvement guidelines for the reporting and archiving of interventional radiology procedures. J Vasc Interv Radiol 2003; 14(suppl):S293-S295.
86. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
87. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138:52-64.
88. Cox DR, Oaks D. Analysis of survival data. London: Chapman and Hall, 1984.